MAPK1 and rheumatoid arthritis: However, but appears not to promote sustained inhibition of the chronic inflammation in RA.430 Other compounds like SCIO-469 show no differences in efficacy when compared to the placebo treatment in RA patients.431 Moreover, the therapeutics, Ph-797804,432 SB-681323,433 and BMS-582949,434 inhibitors of P38, are now in RA treatment clinical trials, but results from these interventions have yet to be reported.